Discovery and evaluation of potent, cysteine-based α4β1 integrin antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 9, 2000, Pages 993-995

  Archibald, Sarah C ^a   Head, John C ^a   Linsley, Janeen M ^a   Porter, John R ^a   Robinson, Martyn K ^a   Shock, Anthony ^a   Warrellow, Graham J ^a  

^a UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CD29 ANTIGEN ANTAGONIST; CYSTINE; INTEGRIN RECEPTOR; LIGAND; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CELL ADHESION; CHEMICAL MODIFICATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKOCYTE ADHERENCE INHIBITION; PHARMACOPHORE; PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

CYSTEINE; INTEGRIN ALPHA4BETA1; INTEGRINS; INTERLEUKIN-8; PROTEIN BINDING; RECEPTORS, LYMPHOCYTE HOMING; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0034192513     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00146-3     Document Type: Article

References (16)

1. Hynes R.O. Cell. 69:1992;11.
2. (a) Bochner, B. S.; Luscinkas, F. W.; Gimbrone, M. A.; Newman, W.; Sterbinsky, S. A.; Derse-Anthony, C. P.; Klunk, D.; Schleimer, R. P. J. Exp. Med. 1991, 173, 1553.
3. (b) Hemler, M. E.; Elices, M. J.; Parker, C.; Takada, Y. Immunol. Rev. 1990, 114, 45.
4. (c) Hemler, M. E. Annu. Rev. Immunol. 1990, 8, 365.
5. Elices, M. J. In Cell Adhesion Molecules and Matrix Proteins: Role in Health and Diseases; Mousa, S. A., ed.; Springer-Verlag and R. G. Landes Co., 1998; pp 133-147.
6. Elices M.J., Osborn L., Takada Y., Crouse C., Luhowskyj S., Hemler M.E., Lobb R.R. Cell. 59:1990;577.
7. Wayner E.A., Garcia-Pardo A., Humphries M.J., McDonald J.A., Carter W.G. Cell Biol. 109:1989;1321.
8. Komoriya A., Green L.J., Mervic M., Yamada S.S., Yamada K.M., Humphries M.J. J. Biol. Chem. 266:1991;15075.
9. (a) Wang, J.-H.; Pepinsky, R. B.; Stehle, T.; Liu, J.-H.; Karpaus, M.; Browning, B.; Osborn, L. Proc. Natl. Acad. Sci. USA 1995, 92, 5714.
10. (b) Jones, E. Y.; Harlos, K.; Bottomley, M. J.; Robinson, R. C.; Driscoll, P. C.; Edwards, R. M.; Clements, J. M.; Dudgeon, T. J.; Stuart, D. I. Nature 1995, 373, 539.
11. Bergelson J.M., Hemler M.E. Curr. Biol. 5:1995;615.
12. Springer T.A. Proc. Natl. Acad. Sci. USA. 94:1997;65.
13. (a) Lobb, R. R.; Adams, S. P. Exp. Opin. Invest. Drugs 1999, 8, 935.
14. (b) Zimmerman, C. N. Exp. Opin. Ther. Patents 1999, 9, 129.
15. Nowlin D.M., Gorscan F., Moscinski M., Chiang S.-L., Lobl T.J., Cardarelli P.M. J. Biol. Chem. 268:1993;20352.
16. A Jurkat cell line expressing α4β1 was incubated at 37 °C for 30 min with human 2-domain VCAM-1-FC immobilised on a plate with anti-human FC in the presence of the test compound. The plates were washed and residual cells are stained with Rose Bengal.